Date:May. 31, 2022
Your Name:Yi Wang
Manuscript Title: Prognostic value and clinicopathological correlation of the tumor regression grade in
neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	, tone	
	,,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Possint of agricument	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
12		News	
13	Other financial or non-	None	
	financial interests		

The aurthor reports funding from the Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).

Please place an "X" next to the following statement to indicate your agreement:

Date:May. 31, 2022
Your Name:Handong Xu
Manuscript Title: Prognostic value and clinicopathological correlation of the tumor regression grade in
neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	, tone	
	,,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Possint of agricument	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
12		News	
13	Other financial or non-	None	
	financial interests		

The aurthor reports funding from the Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).

Please place an "X" next to the following statement to indicate your agreement:

Date:May. 31, 2022
Your Name: Can Hu
Manuscript Title: Prognostic value and clinicopathological correlation of the tumor regression grade in
neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	Tronc	
	,,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Pagaint of agricument	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
12		News	
13	Other financial or non-	None	
	financial interests		

The aurthor reports funding from the Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).

Please place an "X" next to the following statement to indicate your agreement:

Date:May. 31, 2022
Your Name: Pengcheng Yu
Manuscript Title: Prognostic value and clinicopathological correlation of the tumor regression grade in
neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	, tone	
	,,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Pagaint of agricument	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
12		News	
13	Other financial or non-	None	
	financial interests		

The aurthor reports funding from the Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).

Please place an "X" next to the following statement to indicate your agreement:

Date:May. 31, 2022
Your Name:Zhehan Bao
Manuscript Title: Prognostic value and clinicopathological correlation of the tumor regression grade in
neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	, tone	
	,,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Pagaint of agricument	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
12		News	
13	Other financial or non-	None	
	financial interests		

The aurthor reports funding from the Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).

Please place an "X" next to the following statement to indicate your agreement:

Date:	May. 31, 2	2022			
Your Name	Your Name:Yanqiang Zhang				
Manuscript	t Title:	Prognostic value and clinicopathological correlation of the tumor regression grade in			
neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study					
Manuscript number (if known):					

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	, tone	
	,,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Pagaint of agricument	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
12		News	
13	Other financial or non-	None	
	financial interests		

The aurthor reports funding from the Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).

Please place an "X" next to the following statement to indicate your agreement:

Date:May. 31, 2022
Your Name:Ruolan Zhang
Manuscript Title: Prognostic value and clinicopathological correlation of the tumor regression grade in
neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	, tone	
	,,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Pagaint of agricument	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
12		News	
13	Other financial or non-	None	
	financial interests		

The aurthor reports funding from the Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).

Please place an "X" next to the following statement to indicate your agreement:

Date:May. 31, 2022
Your Name:Shengjie Zhang
Manuscript Title: Prognostic value and clinicopathological correlation of the tumor regression grade in
neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	, tone	
	,,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Pagaint of agricument	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
12		News	
13	Other financial or non-	None	
	financial interests		

The aurthor reports funding from the Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).

Please place an "X" next to the following statement to indicate your agreement:

Date:May. 31, 2022
Your Name:Bing Li
Manuscript Title: Prognostic value and clinicopathological correlation of the tumor regression grade in
neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	, tone	
	,,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Pagaint of agricument	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
12		News	
13	Other financial or non-	None	
	financial interests		

The aurthor reports funding from the Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).

Please place an "X" next to the following statement to indicate your agreement:

Date:May. 31, 2022
Your Name: Jean-Marie Aerts
Manuscript Title: Prognostic value and clinicopathological correlation of the tumor regression grade in
neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study
Manuscript number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	, tone	
	,,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Pagaint of agricument	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
12		News	
13	Other financial or non-	None	
	financial interests		

The aurthor reports funding from the Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).

Please place an "X" next to the following statement to indicate your agreement:

Date:May. 31, 2022				
Your Name:Zhiyuan Xu				
Manuscript Title: Prognostic value and clinicopathological correlation of the tumor regression grade in				
neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study				
Manuscript number (if known):				

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	, tone	
	,,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Pagaint of agricument	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
12		News	
13	Other financial or non-	None	
	financial interests		

The aurthor reports funding from the Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).

Please place an "X" next to the following statement to indicate your agreement:

Date:May. 31, 2022			
Your Name:_Xiangdong Cheng			
Manuscript Title: Prognostic value and clinicopathological correlation of the tumor regression grade in			
neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study			
Manuscript number (if known):			

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	The Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
6	Payment for expert	None	
0	testimony	None	
	testimony		
7	Support for attending	None	
,	meetings and/or travel	, tone	
	,,		
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
12	Pagaint of agricument	None	
12	Receipt of equipment, materials, drugs, medical	None	
	writing, gifts or other		
	services		
12		News	
13	Other financial or non-	None	
	financial interests		

The aurthor reports funding from the Diagnosis and Therapy Center of Upper Gastrointestinal Tumor (JBZX-202006), the Natural Science Foundation of Zhejiang Province (LY18H290006), the Key research and development project of Zhejiang Science and Technology Department (2019C03049), the National Natural Science Foundation of China (81973634, 82074245), and the Program of Zhejiang Provincial TCM Sci-tech Plan (2019ZZ010, 2021ZA020).

Please place an "X" next to the following statement to indicate your agreement: